12 May 2020/8 May 2020
Methods Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The study is registered with ClinicalTrials.gov, NCT04276688.
https://clinicaltrials.gov/ct2/show/NCT04276688
India prices
Lopinavir-Ritonavir - Elmetra Rs. 1700 per bottle of 60 tablets.
https://www.indiamart.com/proddetail/emletra-lopinavir-ritonavir-12670234530.html
Ribavirin - 120 per strip of 10 tablets of 200 mg
https://dir.indiamart.com/impcat/ribavirin.html
Interferon beta-1b - 0.25 mg vial Rs. 116.
https://www.medindia.net/drug-price/interferon-beta-1-b/betaferon.htm
https://dir.indiamart.com/impcat/interferon-beta-1-alpha.html
Covid 19 Therapeutics Tracker
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker
15 May 2020
India - The Indian Council of Medical Research (ICMR) announced that potential anti-viral agents, Remdesivir, Chloroquine/Hydroxychloroquine, Lopinavir-Ritonavir and Lopinavir-Ritonavir with Interferon (ß1a) will be evaluated in India as part of the solidarity trial.
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/india-to-test-four-drugs-for-covid-19-as-part-of-the-who-solidarity-trial/articleshow/75721525.cms
17 April 2020
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR)
Actual Study Start Date : April 17, 2020
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2022
https://clinicaltrials.gov/ct2/show/NCT04321174
14 April 2020
Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19
https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/
14 April 2020
Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19
https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/
7 April 2020
The lopinavir-ritonavir clinical trial: Researchers at the Jin Yin-Tan Hospital treated 199 COVID-19 patients with either the HIV antiviral combination of lopinavir-ritonavir or the standard of care. According to the team, the symptoms of patients treated with lopinavir-ritonavir improved faster than those given the standard of care alone. Acceptable safety levels were observed throughout.
March 18, 2020
N Engl J Med 2020; 382:1787-1799
article was published on March 18, 2020, at NEJM.org.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
List of authors.
Bin Cao, M.D., Yeming Wang, M.D., Danning Wen, M.D., Wen Liu, M.S., Jingli Wang, M.D., Guohui Fan, M.S., Lianguo Ruan, M.D., Bin Song, M.D., Yanping Cai, M.D., Ming Wei, M.D., Xingwang Li, M.D., Jiaan Xia, M.D., et al.
Article CONCLUSIONS
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care.
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
Editorial on the above study - Interesting remarks on the above study.
https://www.nejm.org/doi/full/10.1056/NEJMe2005477
Editorial on the above study - Interesting remarks on the above study.
https://www.nejm.org/doi/full/10.1056/NEJMe2005477
